AZN vs BMY
AstraZeneca PLC and Bristol Myers Squibb Co., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AZN | BMY |
|---|---|---|
| Revenue | $58.7B | $48.2B |
| Net income | $10.2B | $7.1B |
| Gross margin | 81.9% | 71.1% |
| Net margin | 17.4% | 14.6% |
| Return on equity | 22.9% | 40.5% |
| Diluted EPS | $6.54 | $3.46 |
| Dividend / share | $3.13 | $2.49 |
| Payout ratio | 48.6% | 71.5% |
| Free cash flow | $11.8B | $12.8B |
| Equity | $48.7B | $18.5B |
| Net debt / equity | 0.49× | 1.87× |
| Current ratio | 0.94× | 1.26× |
| Revenue CAGR 5y | 17.2% | 2.5% |
| Profit CAGR 5y | 26.2% | · |
AZN bills 1.2× the revenue of BMY, and keeps more of each dollar of revenue as profit (17.4% against 14.6%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AZN | BMY |
|---|---|---|
| FY2025 | $58.7B | $48.2B |
| FY2024 | $54.1B | $48.3B |
| FY2023 | $45.8B | $45.0B |
| FY2022 | $44.4B | $46.2B |
| FY2021 | $37.4B | $46.4B |
| FY2020 | $26.6B | $42.5B |
| FY2019 | $24.4B | $26.1B |
| FY2018 | $22.1B | $22.6B |
| FY2017 | $22.5B | $20.8B |
| FY2016 | $23.0B | $19.4B |
Bottom line
| Fiscal year | AZN | BMY |
|---|---|---|
| FY2025 | $10.2B | $7.1B |
| FY2024 | $7.0B | $-8.9B |
| FY2023 | $6.0B | $8.0B |
| FY2022 | $3.3B | $6.3B |
| FY2021 | $112.0M | $7.0B |
| FY2020 | $3.2B | $-9.0B |
| FY2019 | $1.3B | $3.4B |
| FY2018 | $2.2B | $4.9B |
| FY2017 | $3.0B | $1.0B |
| FY2016 | $3.5B | $4.5B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$10,545,000,000 | AZN |
| FY2024 | +$5,773,000,000 | AZN |
| FY2023 | +$805,000,000 | AZN |
| FY2022 | −$1,808,000,000 | BMY |
| FY2021 | −$8,968,000,000 | BMY |
| FY2020 | −$15,901,000,000 | BMY |
| FY2019 | −$1,761,000,000 | BMY |
| FY2018 | −$471,000,000 | BMY |
| FY2017 | +$1,689,000,000 | AZN |
| FY2016 | +$3,575,000,000 | AZN |
| FY2015 | +$8,148,000,000 | AZN |
The higher-revenue side has changed between AZN and BMY over this period. The gap has widened since the earliest year compared.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +2.8 pp | AZN |
| FY2024 | +31.5 pp | AZN |
| FY2023 | −4.9 pp | BMY |
| FY2022 | −6.3 pp | BMY |
| FY2021 | −14.8 pp | BMY |
| FY2020 | +33.0 pp | AZN |
| FY2019 | −8.2 pp | BMY |
| FY2018 | −12.6 pp | BMY |
| FY2017 | +8.1 pp | AZN |
| FY2016 | −8.4 pp | BMY |
| FY2015 | +1.6 pp | AZN |
The higher net margin has changed hands between AZN and BMY over this period.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's net margin has been more volatile than AZN's over the 11 comparable fiscal years — 14.3 percentage points of standard deviation against 4.6.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AZN and BMY over these 11 fiscal years — AZN led in 5 and BMY in 6.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's return on equity has been more volatile than AZN's over the 11 comparable fiscal years — 22.9 percentage points of standard deviation against 6.4.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AZN and BMY over these 11 fiscal years — AZN led in 4 and BMY in 7.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.